|Table of Contents|

Prognostic efficacy of new manchester score system(NMSS) in patients with early non-small-cell lung cancer(NSCLC) after surgery

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
73-76
Research Field:
Publishing date:

Info

Title:
Prognostic efficacy of new manchester score system(NMSS) in patients with early non-small-cell lung cancer(NSCLC) after surgery
Author(s):
SHI Dongfeng; LIANG Qingzheng; XUE Mingqiang
The Second Thoracic Surgery Department，Henan Provincial Chest Hospital，Henan Zhengzhou 450001，China.
Keywords:
manchester scoring system; non-small cell lung cancer; prognosis; electrolytes; markers
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.01.016
Abstract:
Objective：To investigate the prognostic value of preoperative new manchester score system(NMSS) in patients with non-small cell lung cancer(NSCLC) after surgery.Methods：A total of 278 patients who underwent surgical resection of early NSCLC at Henan provincial chest hospital from December 2015 to December 2018 were enrolled.All enrolled patients were divided into three groups according to NMSS，which was determined by lactate dehydrogenase(LDH)，alkaline phosphatase(ALP)，serum sodium，blood bicarbonate，tumor stages and karnofsky performance status(KPS).The relationship between NMSS and other clinical indicators with postoperative survival time was analyzed.Results：The 278 patients with NSCLC，46(16.5%) were in the median group and 70(25.2%) were in the poor group.The older age，advanced stages，and without chemoradiotherapy were associated with prognosis.Patients in the NMSS poor group was an independent risk factor for poorer prognosis.Conclusion：Preoperative high NMSS score is an independent risk factor for the prognosis of non-small cell lung cancer.In the treatment of non-small cell lung cancer，the corresponding predictive evaluation can be carried out according to the patient's auxiliary examination results.

References:

[1]SIEGEL RL，MILLER KD，JEMAL A.Cancer statistics，2018［J］.CA A Cancer Journal for Clinicians，2018，68(suppl 12)：277-300.
[2]HERBST RS，MORGENSZTERN D，BOSHOFF C.The biology and management of non-small cell lung cancer［J］.Nature，2018，553(7689)：446-454.
[3]王亚旗，王兴，阎石，等.非小细胞肺癌新辅助治疗联合外科治疗的进展［J］.中国肺癌杂志，2017，20(5)：352-360. WANG Y，WANG X，YAN S，et al.Advances in neoadjuvant therapy combined with surgical treatment for non-small cell lung cancer［J］.Chinese Journal of Lung Cancer，2017，20(5)：352-360.
[4]王亚龙，王亚格，胡箫，等.153例经外科干预的非小细胞肺癌伴胸膜播散患者的预后研究［J］.中国肿瘤临床，2017，44(14)：712-716. WANG YL，WANG YG，HU X，et al.Prognosis of 153 non- small cell lung cancer patients with pleural dissemination after surgery［J］.Chin J Clin Oncol，2017，44(14)：712-716.
[5]FAN H，SHAO ZY，XIAO YY，et al.Comparison of the glasgow prognostic score(GPS) and the modified glasgow prognostic score(mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer［J］.Journal of Cancer Research & Clinical Oncology，2016，142(6)：1285-1297.
[6]田希贵，刘德森，汪元玉，等.腺癌与其他类型非小细胞肺癌术后临床特点的差异及预后因素分析［J］.中国癌症杂志，2017，27(3)：227-232. TIAN XG，LIU DS，WANG YY，et al.Analysis of the difference of clinical features and prognostic factors between adenocarcinoma and other types of non-small cell lung cancer after operation［J］.Chinese Journal of Cancer，2017，27(3)：227-232.
[7]TANG H，WANG S，XIAO G，et al.Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies［J］.Ann Oncol，2017，28(4)：733-740.
[8]ETTINGER DS，WOOD DE，AISNER DL，et al.Non-small cell lung cancer，version 5.2017，NCCN clinical practice guidelines in oncology［J］.Journal of the National Comprehensive Cancer Network，2017，15(4)：504-535.
[9]陆舜，虞永峰，纪文翔.2015年肺癌诊疗指南：共识和争议［J］.解放军医学杂志，2016，41(1)：1-6. LU S，YU YF，JI WX.Guidelines for diagnosis and treatment of lung cancer in 2015：Consensus and controversy［J］.PLA Medical Journal，2016，41(1)：1-6.
[10]CERNY T,BLAIR V，ANDERSON H, et al.Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients［J］.International Journal of Cancer，1987，39(2)：146-149.
[11]KAWAHARA MASAAKI,MASAHIRO FUKUOKA，NAGAHIRO SAIJO,et al.Prognostic factors and prognostic staging system for small cell lung cancer［J］.Japanese Journal of Clinical Oncology, 1996，27(3)：158-165.
[12]MAESTU I，PASTOR M，GóMEZ-CODINA J，et al.Pretreatment prognostic factors for survival in small-cell lung cancer：A new prognostic index and validation of three known prognostic indices on 341 patients［J］.Annals of Oncology，1997，8(6)：547-553.
[13]MUKHERJEE S.Abstract 2961：Characterization of methylation profiles reveals distinct epigenomic patterns in SCLC and NSCLC［J］.Cancer Research，2015，75(15 Supplement)：2961.
[14]李靖康，徐爱晖.1107例肺癌患者临床特征分析［J］.临床肺科杂志，2018，23(5)：905-908. LI JK，XU AH.Analysis of clinical characteristics of 1107 patients with lung cancer［J］.Journal of Clinical Lung，2018，23(5)：905-908.
[15]刘春全，崔永.肺结节评估四大指南比较分析［J］.中国肺癌杂志，2017，20(7)：490-498. LIU CQ，CUI Y.Comparative analysis of four guidelines for pulmonary nodule assessment［J］.Chinese Journal of Lung Cancer，2017，20(7)：490-498.
[16]吴必嘉，龚峻梅，陈娟娟，等.急性淋巴细胞白血病患者血清乳酸脱氢酶和维生素D水平与其预后的关系［J］.广东医学，2017，38(7)：1009-1013. WU BJ，GONG JM，CHEN JJ，et al.The relationship between serum lactate dehydrogenase and vitamin D levels and prognosis in patients with acute lymphoblastic leukemia［J］.Guangdong Medicine，2017，38(7)：1009-1013.
[17]ZHANG X，GUO M，FAN J，et al.Prognostic significance of serum LDH in small cell lung cancer：A systematic review with meta-analysis［J］.Cancer Biomarkers，2016，16(3)：415-423.
[18]YANG Y，SU D，ZHAO L，et al.Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells［J］.Oncotarget，2014，5(23)：11886-11896.
[19]HAO H，CHEN L，HUANG D，et al.Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma［J］.European Journal of Cancer Care，2017，26(5)：e12536.
[20]NING P，SHANSHAN G，YADONG X，et al.Alkaline phosphatase-to-albumin ratio as a prognostic indicator in pancreatic ductal adenocarcinoma after curative resection［J］.Journal of Cancer，2017，8(16)：3362-3370.
[21]孙继建，潘世杰.血清ALP、ICTP、sTf水平及癌组织BMP表达对前列腺癌骨转移的预测价值［J］.山东医药，2017，57(48)：79-81. SUN JJ，PAN SJ.Serum ALP，ICTP，sTf levels and BMP expression in cancer tissues as predictors of bone metastasis of prostate cancer［J］.Shandong Medicine，2017，57(48)：79-81.
[22]HERZ F，SCHERMER A，HALWER M，et al.Alkaline phosphatase in HT-29，a human colon cancer cell line：Influence of sodium butyrate and hyperosmolality［J］.Archives of Biochemistry and Biophysics，1981，210(2)：581-591.
[23]孙萍萍，王旭.小细胞肺癌合并抗利尿激素分泌异常综合征的研究进展［J］.中国肿瘤临床，2017，44(5)：233-237. SUN PP，WANG X.Advances in the study of small cell lung cancer complicated with dysdiuretic hormone secretion syndrome［J］.Clinical Oncology of China，2017，44(5)：233-237.
[24]DETTERBECK FC.The eighth edition TNM stage classification for lung cancer：What does it mean on main street［J］.J Thorac Cardiovasc Surg，2018，155(1)：356-359.
[25]CHANSKY K，DETTERBECK FC，NICHOLSON AG，et al.The IASLC lung cancer staging project：External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer［J］.Journal of Thoracic Oncology，2017，12(7)：1109-1121.

Memo

Memo:
-
Last Update: 2020-11-30